J Korean Med Assoc.  2018 Oct;61(10):632-636. 10.5124/jkma.2018.61.10.632.

Proper use of topical corticosteroids

• Lee JH
• Park YM

• KMID: 2426487
• DOI: http://doi.org/10.5124/jkma.2018.61.10.632

Abstract

Topical corticosteroids are widely prescribed and used. As interest in the use of corticosteroids grows, people are increasingly exposed to misinformation that causes an excessive fear of side effects. Topical corticosteroids mainly have vasoconstrictive, anti-inflammatory, immunosuppressive, and anti-proliferative effects. Corticosteroids are prescribed based on the patient's age, the site and severity of the lesion, and patient compliance. Adverse reactions include skin atrophy, telangiectasia, hypopigmentation, and steroid-induced acne. To prevent the side effects of topical corticosteroids and to minimize phobias about topical corticosteroids in the future, we suggest providing proper information and education for both physicians and patients about the safety, efficacy, and proper use of topical steroids. In this article, we review basic information about topical corticosteroids and guidelines for their use.

Keyword

Steroids; Topical; Utilization; Therapeutics; Adverse effects

MeSH Terms

Acne Vulgaris
Adrenal Cortex Hormones*
Atrophy
Education
Humans
Hypopigmentation
Patient Compliance
Phobic Disorders
Skin
Steroids
Telangiectasis
Adrenal Cortex Hormones
Steroids

Reference

1. Hench PS, Kendall EC, Slocumb CH, Polley HF. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch Intern Med (Chic). 1950; 85:545–666.

2. Sulzberger MB, Witten VH, Yaffe SN. Cortisone acetate administered orally in dermatologic therapy. AMA Arch Derm Syphilol. 1951; 64:573–579.

3. Kragballe K. Topical corticosteroids: mechanisms of action. Acta Derm Venereol Suppl (Stockh). 1989; 151:7–10.

4. Bewley A. Dermatology Working Group. Expert consensus: time for a change in the way we advise our patients to use topical corticosteroids. Br J Dermatol. 2008; 158:917–920.

5. Altura BM. Role of glucocorticoids in local regulation of blood flow. Am J Physiol. 1966; 211:1393–1397.

6. Guin JD, Wallis MS, Walls R, Lehman PA, Franz TJ. Quantitative vasoconstrictor assay for topical corticosteroids: the puzzling case of fluocinolone acetonide. J Am Acad Dermatol. 1993; 29:197–202.

7. Epstein EH Jr, Bonifas JM. Glucocorticoid receptors of normal human epidermis. J Invest Dermatol. 1982; 78:144–146.

8. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids: new mechanisms for old drugs. N Engl J Med. 2005; 353:1711–1723.

9. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet. 2009; 373:1905–1917.

10. Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function. Annu Rev Immunol. 2000; 18:309–345.

11. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006; 54:1–15.

12. Kalavala M, Mills CM, Long CC, Finlay AY. The fingertip unit: a practical guide to topical therapy in children. J Dermatolog Treat. 2007; 18:319–320.

13. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000; 142:931–936.

14. Hajar T, Leshem YA, Hanifin JM, Nedorost ST, Lio PA, Paller AS, Block J, Simpson EL. (the National Eczema Association Task Force). A systematic review of topical corticosteroid withdrawal (“steroid addiction”) in patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol. 2015; 72:541–549.

15. Matura M, Goossens A. Contact allergy to corticosteroids. Allergy. 2000; 55:698–704.

16. Coopman S, Degreef H, Dooms-Goossens A. Identification of cross-reaction patterns in allergic contact dermatitis from topical corticosteroids. Br J Dermatol. 1989; 121:27–34.

17. Jacob SE, Steele T. Corticosteroid classes: a quick reference guide including patch test substances and cross-reactivity. J Am Acad Dermatol. 2006; 54:723–727.

18. Jackson S, Gilchrist H, Nesbitt LT Jr. Update on the dermatologic use of systemic glucocorticosteroids. Dermatol Ther. 2007; 20:187–205.

19. Cubey RB. Glaucoma following the application of corticoste-roid to the skin of the eyelids. Br J Dermatol. 1976; 95:207–208.

20. Castela E, Archier E, Devaux S, Gallini A, Aractingi S, Cribier B, Jullien D, Aubin F, Bachelez H, Joly P, Le Maitre M, Misery L, Richard MA, Paul C, Ortonne JP. Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy. J Eur Acad Dermatol Venereol. 2012; 26:Suppl 3. 47–51.

21. Levin E, Gupta R, Butler D, Chiang C, Koo JY. Topical steroid risk analysis: differentiating between physiologic and pathologic adrenal suppression. J Dermatolog Treat. 2014; 25:501–506.